Last reviewed · How we verify

NCT04452799

Hesperidin and Diosmin for Treatment of COVID-19

Status unknown EARLY_PHASE1 Last updated 30 June 2020
What this trial tests

EARLY_PHASE1 trial testing Hesperidin and Diosmin mixture in Coronavirus Infection in 100 participants. Status unknown.

Timeline
1 July 2020
Primary endpoint
1 October 2020
30 October 2020

Quick facts

Lead sponsorTanta University
PhaseEARLY_PHASE1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment100
Start date1 July 2020
Primary completion1 October 2020
Estimated completion30 October 2020

Drugs / interventions tested

Conditions studied

Sponsor

Tanta University

Who can join

Adults 18 to 65, any sex, with Coronavirus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

SARS-CoV-2 or COVID-19 is representing the major global burden that implicated more than 10 million infected cases and 500 thousand deaths worldwide. The prevalence of this pandemic disease is expected to rise every day. The challenge is to control its rapid spread meanwhile looking for a specific treatment to improve patient outcomes. Hesperidin is a classical herbal medicine used worldwide for a long time with an excellent safety profile. Hesperidin is a well-known herbal medication used as an antioxidant and anti-inflammatory agent. Available shreds of evidence support the promising use of hesperidin in prophylaxis and treatment of COVID 19. Herein, we discuss the possible prophylactic and treatment mechanisms of hesperidin based on previous and recent findings. Hesperidin can block coronavirus from entering host cells through ACE2 receptors which can prevent the infection. Anti-viral activity of hesperidin might constitute a treatment option for COVID-19 through improving host cellular immunity against infection and its good anti-inflammatory activity may help in controlling cytokine storm. Hesperidin mixture with diosmin co-administrated with heparin protect against venous thromboembolism which may prevent disease progression. Based on that, hesperidin might be used as a meaningful prophylactic agent and a promising adjuvant treatment option against SARS-CoV-2 infection.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease.
    Yuce M, Cicek E, Inan T, Dag AB, et al · · 2021 · cited 37× · PMID 34169568 · DOI 10.1002/prot.26164
  2. Flavonoids as potential phytotherapeutics to combat cytokine storm in SARS-CoV-2.
    Gour A, Manhas D, Bag S, Gorain B, et al · · 2021 · cited 35× · PMID 33786876 · DOI 10.1002/ptr.7092
  3. Hesperetin as an anti-SARS-CoV-2 agent can inhibit COVID-19-associated cancer progression by suppressing intracellular signaling pathways.
    Zalpoor H, Bakhtiyari M, Shapourian H, Rostampour P, et al · · 2022 · cited 30× · PMID 35994216 · DOI 10.1007/s10787-022-01054-3
  4. A multi-targeted approach to identify potential flavonoids against three targets in the SARS-CoV-2 life cycle.
    Kumar S, Paul P, Yadav P, Kaul R, et al · · 2022 · cited 25× · PMID 35032740 · DOI 10.1016/j.compbiomed.2022.105231
  5. Phytochemicals: Potential Therapeutic Interventions Against Coronavirus-Associated Lung Injury.
    Majnooni MB, Fakhri S, Shokoohinia Y, Kiyani N, et al · · 2020 · cited 24× · PMID 33658931 · DOI 10.3389/fphar.2020.588467
  6. Natural Products Modulating Angiotensin Converting Enzyme 2 (ACE2) as Potential COVID-19 Therapies.
    Abubakar MB, Usman D, El-Saber Batiha G, Cruz-Martins N, et al · · 2021 · cited 18× · PMID 34012391 · DOI 10.3389/fphar.2021.629935
  7. Neurological Implications of COVID-19: Role of Redox Imbalance and Mitochondrial Dysfunction.
    Kaundal RK, Kalvala AK, Kumar A. · · 2021 · cited 17× · PMID 34110602 · DOI 10.1007/s12035-021-02412-y
  8. Drug repurposing on Alzheimer's disease through modulation of NRF2 neighborhood.
    Bourdakou MM, Fernández-Ginés R, Cuadrado A, Spyrou GM. · · 2023 · cited 14× · PMID 37696195 · DOI 10.1016/j.redox.2023.102881

Verify or expand the search:

Other recruiting trials for Coronavirus Infection

Currently open trials in the same condition.

Other Tanta University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04452799.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing